{"filings":[{"id":98496,"accession_number":"0000721371-26-000017","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cardinal Health Q3 revenue +11% to $60.9B, non-GAAP EPS $3.17 (+35%), raises FY26 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Non-GAAP EPS $3.17, up 35% YoY; GAAP EPS $1.69, down 20% on $184M goodwill impairment in Navista & ION.","Revenue $60.9B, +11%; Pharmaceutical & Specialty segment profit +18% to $784M.","FY26 non-GAAP EPS guidance raised to $10.70-$10.80; adjusted free cash flow raised to $3.3B-$3.7B.","Global Medical segment profit fell 36% to $25M due to tariff impact; Other segment profit up 34% to $179M.","Completed $250M accelerated share repurchase; YTD buybacks $1.0B; leverage ratio lowered to 3.0X."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114008,"accession_number":"0000721371-26-000013","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cardinal Health appoints Patricia Hemingway Hall as Board Chair; Kenny retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gregory B. Kenny retired as Board Chair and director effective March 20, 2026; no disagreement with company.","Patricia A. Hemingway Hall appointed as Board Chair; former CEO of Health Care Service Corporation.","Company to release Q3 fiscal 2026 earnings on April 30, 2026; reaffirms confidence in fiscal 2026 outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114007,"accession_number":"0000721371-26-000010","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cardinal Health CAO Mary Scherer to retire in Feb 2027; search launched","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mary Scherer, SVP and Chief Accounting Officer, notified Cardinal Health of retirement effective February 2027.","Company will initiate a search for a successor; Scherer will remain CAO until replacement is onboarded.","Transition is planned with nearly one-year notice, ensuring orderly handoff."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114006,"accession_number":"0000721371-26-000004","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cardinal Health Q2 revenue $65.6B (+19%), non-GAAP EPS $2.63 (+36%), raises FY26 EPS outlook to $10.15-$10.35","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $65.6B (+19% YoY); GAAP diluted EPS $1.97 (+19%); non-GAAP diluted EPS $2.63 (+36%).","Pharma & Specialty profit $687M (+29%); Global Medical Products profit $37M (+106%); Other profit $179M (+52%).","FY2026 non-GAAP EPS guidance raised to $10.15-$10.35, representing 23%-26% growth.","Year-to-date share repurchases of $750M completed; reached targeted leverage range.","Acquired Solaris Health (urology MSO, >750 providers) on Nov 3; introduced ContinuCare Pathway program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":129636000000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114005,"accession_number":"0000721371-26-000003","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cardinal Health raises FY2026 non-GAAP EPS outlook to at least $10.00, up from $9.65-$9.85","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raises FY2026 non-GAAP diluted EPS guidance to at least $10.00 from prior range of $9.65-$9.85.","Specialty revenues expected to exceed $50B in FY2026, a 16% CAGR over three years.","Successfully transitioned distribution agreements for all drugs affected by 2026 Medicare Drug Price Negotiation Program.","Launched ContinuCare Pathway program; Publix enrolled ~1,400 pharmacies, expanding to over 11,000 retail and grocery pharmacies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130410,"accession_number":"0000721371-25-000133","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cardinal Health shareholders elect 12 directors, approve say-on-pay, ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 12 director nominees elected with >95% support; broker non-votes 21.1M for each.","Non-binding advisory say-on-pay approved: 168.4M for (89.9%), 17.3M against.","Ratification of Ernst & Young as FY2026 auditor approved: 195.7M for, 12.3M against, zero broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130409,"accession_number":"0000721371-25-000128","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cardinal Health Q1 revenue $64B (+22%), non-GAAP EPS $2.55 (+36%); raises FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $64B (+22% YoY); GAAP diluted EPS $1.88 (+11%); non-GAAP diluted EPS $2.55 (+36%).","Segment profit growth across all five segments; Pharmaceutical & Specialty profit up 26% to $667M.","FY2026 non-GAAP EPS guidance raised to $9.65-$9.85 (from $9.30-$9.50); adjusted free cash flow raised to $3.0-$3.5B.","Acquisition of Solaris Health expected to close early November; initiated $375M accelerated share repurchase in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":1.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":64009000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130408,"accession_number":"0000721371-25-000125","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Cardinal Health enters $1B 364-day revolving credit facility expiring Oct 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Credit agreement dated October 7, 2025 replaces prior 364-day facility from Oct 2024.","Aggregate commitment of $1.0 billion; termination date October 6, 2026.","Outstanding loans may be converted to term loans due one year after termination date.","Financial covenant: Consolidated Net Leverage Ratio no greater than 3.75 to 1.00.","Facility supports general corporate purposes and backs commercial paper program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130407,"accession_number":"0000721371-25-000122","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Cardinal Health extends receivables purchase facility term to September 2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["First Amendment to Fifth Amended and Restated Receivables Purchase Agreement dated Sept 30, 2025.","Facility term extended to September 28, 2028; no change in facility size disclosed.","Parties include subsidiaries Cardinal Health Funding, Griffin Capital, CH-23 Funding, and banks Wells Fargo, BNS, PNC, BofA, MUFG.","Amendment also includes a new Amended and Restated Fee Letter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146954,"accession_number":"0001193125-25-189845","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Cardinal Health issues $1B in notes to partially fund Solaris Health acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $600M of 4.500% notes due 2030 and $400M of 5.150% notes due 2035.","Net proceeds will fund a portion of the consideration for the proposed acquisition of Solaris Health.","Special mandatory redemption at 101% if acquisition not completed by Aug 12, 2026, or if abandoned.","Proceeds not escrowed; may be used for general corporate purposes pending acquisition close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146953,"accession_number":"0001193125-25-180900","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cardinal Health issues $1B notes: $600M at 4.500% due 2030, $400M at 5.150% due 2035","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $600M aggregate principal of 4.500% Notes due 2030 and $400M of 5.150% Notes due 2035.","Underwriters include Goldman Sachs & Co. LLC, BofA Securities, Inc., and Wells Fargo Securities, LLC.","Offering made under effective shelf registration statement S-3ASR (333-289513).","Net proceeds not specified; debt issuance for general corporate purposes typical for such offerings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146952,"accession_number":"0000721371-25-000075","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cardinal Health Q4 non-GAAP EPS $2.08 (+13%); raises FY26 guidance; acquires Solaris Health for ~$1.9B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $60.2B flat YoY (+21% excluding contract expiration); non-GAAP EPS $2.08 (up 13%).","FY2025 non-GAAP EPS $8.24 (+9%); adjusted free cash flow $2.5B.","FY2026 non-GAAP EPS guidance raised to $9.30-$9.50 (from $9.10-$9.30).","Enters agreement to acquire Solaris Health (urology MSO, >750 providers) for ~$1.9B cash; expected close by end of CY2025.","Acquisition slightly accretive to non-GAAP EPS in first 12 months; Cardinal will own ~75% of The Specialty Alliance post-close."],"consensus_eps_estimate":null,"consensus_eps_actual":6.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":222578000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165451,"accession_number":"0000721371-25-000053","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cardinal Health raises FY25 EPS guidance to $8.15-$8.20; sets FY26 preliminary EPS $9.10-$9.30","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Raising FY25 non-GAAP diluted EPS to $8.15-$8.20 (from $8.05-$8.15); 9% growth at midpoint.","Preliminary FY26 non-GAAP diluted EPS $9.10-$9.30 (+13% growth); adjusted FCF $2.75B-$3.25B.","Long-term FY26-FY28: 12-14% EPS CAGR; at least $10B total adjusted FCF; buybacks raised to $750M/year.","Launched The Specialty Alliance (GI Alliance, Urology Alliance); expanding Biopharma Solutions; new distribution center planned.","GMPD long-term target: $50M+ profit growth/year after FY26; FY25 GMPD profit narrowed to ~$130M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165450,"accession_number":"0000721371-25-000036","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cardinal Health Q3 non-GAAP EPS $2.35, up 13% YoY; raises FY25 EPS guidance to $8.05-$8.15","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $54.9B flat YoY; up 19% ex-customer contract expiration.","GAAP diluted EPS $2.10; non-GAAP $2.35, up 13% on 21% non-GAAP op earnings growth.","Pharma & Specialty segment profit $662M (+14%); Medical segment profit $39M (+77%).","FY25 non-GAAP EPS guidance raised to $8.05-$8.15 from $7.85-$8.00.","Completed acquisition of Advanced Diabetes Supply Group on Apr 1; $375M ASR program executed."],"consensus_eps_estimate":2.2011,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":162419000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183101,"accession_number":"0000721371-25-000020","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cardinal Health adds two independent directors: Musslewhite (ex-Definitive Healthcare) and Ramakrishna (SolarWinds CEO)","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Musslewhite, former CEO of Definitive Healthcare, elected to board effective March 7, 2025.","Sudhakar Ramakrishna, President and CEO of SolarWinds Corporation, also elected as independent director.","Musslewhite will serve on Audit and Human Resources & Compensation Committees.","Ramakrishna will serve on Audit and Risk Oversight Committees.","Both directors are deemed independent under NYSE rules; no material transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183100,"accession_number":"0000721371-25-000009","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cardinal Health Q2 non-GAAP EPS $1.93 (+2% YoY); guides FY25 $7.85-8.00, closes GI Alliance deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $55.3B (-4% YoY; +16% ex-large customer expiration); GAAP EPS $1.65, non-GAAP EPS $1.93.","Pharm & Specialty segment profit $531M (+7%); Global Medical Products profit $18M vs $11M.","FY2025 non-GAAP EPS guidance raised to $7.85-$8.00 from $7.75-$7.90; segment profit growth revised.","Completed acquisition of 73% of GI Alliance (gastroenterology MSO) and ION acquisition in Dec.","Started commercial-scale production of actinium-225 for theranostics; new distribution center underway."],"consensus_eps_estimate":2.0582,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":107541000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183099,"accession_number":"0000721371-25-000003","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Cardinal Health raises FY2025 non-GAAP EPS guidance to high end of $7.75-$7.90 range","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Now expects FY2025 non-GAAP EPS toward high end of $7.75 to $7.90, driven by Pharmaceutical & Specialty Solutions strength.","Previous guidance range was $7.75-$7.90; update reflects improved segment performance.","Presenting at JP Morgan 43rd Annual Healthcare Conference on January 14, 2025.","Further details on FY2025 expectations to be provided on Q2 earnings call January 30, 2025."],"consensus_eps_estimate":2.0582,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":107541000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199687,"accession_number":"0000721371-24-000169","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Cardinal Health enters $1.0B term loan for acquisitions of GI Alliance and Advanced Diabetes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$1.0B aggregate term loan facility to pay cash consideration and transaction costs for pending acquisitions of GI Alliance (majority equity) and Advanced Diabetes Supply Group.","Commitment termination date is earlier of both acquisitions close without funding, both termination dates occur, or November 10, 2025.","Loans mature 3 years after borrowing; interest based on Term SOFR plus Applicable Margin tied to credit ratings.","Financial covenant requires Consolidated Net Leverage Ratio no greater than 3.75:1.0.","Customary representations, affirmative/negative covenants (liens, subsidiary debt), and events of default included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199686,"accession_number":"0001193125-24-264393","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Cardinal Health Issues $2.9B in Senior Notes to Fund Acquisitions of GI Alliance and Advanced Diabetes Supply","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $500M of 4.700% Notes due 2026, $750M of 5.000% Notes due 2029, $1B of 5.350% Notes due 2034, and $650M of 5.750% Notes due 2054.","Net proceeds will partially fund the proposed acquisitions of GI Alliance Holdings and Advanced Diabetes Supply Group.","If the GI Alliance acquisition is not closed by November 11, 2025, the company must redeem the notes at 101% of principal plus accrued interest.","Bridge loan commitments from Bank of America were reduced by net proceeds and remaining excess commitments terminated on November 22, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199685,"accession_number":"0001193125-24-260394","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cardinal Health prices $2.9B multi-tranche senior notes offering (2026-2054)","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $500M of 4.700% notes due 2026, $750M of 5.000% notes due 2029, $1,000M of 5.350% notes due 2034, and $650M of 5.750% notes due 2054.","Underwriters include BofA Securities, J.P. Morgan Securities, and Wells Fargo Securities.","Offering made under effective shelf registration statement (Form S-3).","Total aggregate principal amount of $2.9 billion across four tranches."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199684,"accession_number":"0001193125-24-255062","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Cardinal Health acquires 71% of GI Alliance for ~$2.8B and ADSG for ~$1.1B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquires 71% stake in GI Alliance (gastroenterology MSO) for ~$2.8B cash; remaining ~29% callable at fair value after 3 years.","Acquires Advanced Diabetes Supply Group for ~$1.1B cash to merge with at-Home Solutions segment.","Both deals expected to close early CY2025 and be accretive to revenue, segment profit, and non-GAAP EPS in first 12 months.","Bridge loan facility of up to $2.9B from Bank of America to fund acquisitions; company plans to delever over 18-24 months.","FY2025 share repurchase plans unchanged; Investor Day scheduled for June 12, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199683,"accession_number":"0000721371-24-000132","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cardinal Health shareholders elect 10 directors and approve say-on-pay at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders elected all 10 nominees to Board of Directors, including Robert W. Azelby and Michelle M. Brennan, with over 192 million votes for each.","Advisory vote on executive compensation (say-on-pay) approved with 172,738,569 votes for, 19,964,307 against.","Ratification of Ernst & Young LLP as independent auditor for fiscal 2025 approved with 202,732,608 votes for.","Shareholder proposal to prohibit re-nomination of directors failing majority vote was not approved, with 155,556,799 votes against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199682,"accession_number":"0000721371-24-000119","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cardinal Health Q1 GAAP EPS $1.70; Non-GAAP EPS $1.88, up 9% YoY; Raises FY25 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $52.3B, down 4% (up 15% ex-large customer expiration); Pharmaceutical segment profit up 16% to $530M.","Non-GAAP operating earnings $625M (+12%) driven by brand/specialty growth and early COVID vaccine distribution.","Non-GAAP diluted EPS guidance raised to $7.75-$7.90 from $7.55-$7.70; adjusted free cash flow outlook now $1.0B-$1.5B.","Announced $1.1B cash acquisition of Integrated Oncology Network, adding 100+ providers across 10 states.","Completed $375M accelerated share repurchase in October; Global Medical Products segment profit fell to $8M from $12M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":52277000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199681,"accession_number":"0000721371-24-000112","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Cardinal Health enters $1.0B 364-day credit facility, ups commercial paper program to $3.0B","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$1.0B revolving credit facility matures Oct 7, 2025, with optional term-out conversion.","Commercial paper program max increased from $2.0B to $3.0B via Fourth Amendment.","Covenant requires Consolidated Net Leverage Ratio <= 3.75x at each fiscal quarter end.","Interest based on Term SOFR plus margin based on credit rating; facility fee on total commitment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215702,"accession_number":"0000721371-24-000092","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two Cardinal Health directors not standing for re-election at 2024 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven K. Barg and Sujatha Chandrasekaran informed company Sept 6 and 8 they will not stand for re-election.","Both have served since 2022 under cooperation agreement with Elliott; decisions not due to any disagreement.","They will continue as directors until 2024 annual meeting; Barg served on Business Review Committee which sunsetted July 15.","Chandrasekaran is on Audit and Risk Oversight Committees; company thanks them for contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215701,"accession_number":"0000721371-24-000054","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cardinal Health Q4 revenue +12% to $59.9B, non-GAAP EPS $1.84 (+29%); raises FY25 guidance to $7.55-$7.70","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $59.9B (+12% YoY); GAAP EPS $0.96, non-GAAP EPS $1.84 (+29%).","FY2024 revenue $226.8B (+11%), non-GAAP EPS $7.53 (+29%); operating cash flow record $3.8B.","FY2025 non-GAAP EPS guidance raised to $7.55-$7.70 from at least $7.50.","Pharmaceutical & Specialty Solutions segment profit +8% to $482M; GMPD profit $47M vs $7M YoY.","GMPD segment profit improved $40M to $47M driven by net inflationary mitigation initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":3.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":226827000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235101,"accession_number":"0000721371-24-000036","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cardinal Health Q3 non-GAAP EPS $2.08 (+20% YoY); raises FY24 EPS guidance to $7.30-$7.40","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $54.9B (+9% YoY); GAAP diluted EPS $1.05; non-GAAP diluted EPS $2.08 (+20%).","Pharma & Specialty Solutions segment profit $580M (+4%); Global Medical Products segment profit $20M vs -$46M a year ago.","FY2024 non-GAAP EPS guidance raised to $7.30-$7.40 (from $7.20-$7.35); non-GAAP effective tax rate guidance lowered to 22%-23%.","Preliminary FY2025 non-GAAP EPS guidance at least $7.50; Pharma segment profit growth at least 1%; GMPD segment profit ~$175M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":167119000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235100,"accession_number":"0000721371-24-000030","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cardinal Health recasts segment results under new structure for FY2022-H1 FY2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New segments: Pharmaceutical & Specialty Solutions and Global Medical Products & Distribution; three smaller ops reported as Other.","Recast unaudited quarterly data for FY2022, FY2023, and H1 FY2024; no change to consolidated revenue or net income.","Pharm & Spec Solutions segment profit grew 13% in FY2023 to $1,862M; H1 FY2024 profit $961M.","Global Medical Products & Distribution segment losses: FY2022 loss $49M, FY2023 loss $162M, H1 FY2024 loss $2M.","Total segment revenue grew 13% in FY2023 to $205.1B; H1 FY2024 up 11% to $112.2B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235099,"accession_number":"0000721371-24-000026","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cardinal Health OptumRx contracts not renewed; reaffirms FY2024 non-GAAP EPS guidance $7.20-$7.35","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["OptumRx contracts expire June 2024; not renewed; 16% of FY2023 consolidated revenue.","About 90% of these sales were non-specialty bulk shipments with meaningfully lower operating margin.","Reiterates long-term segment profit CAGR 4-6% and non-GAAP EPS CAGR 12-14% (FY2024-2026 vs FY2023).","Expects FY2025 growth in Pharmaceutical & Specialty segment profit and non-GAAP EPS, partially offsetting impact.","Adjusted free cash flow target ~$2B average FY2024-2026, but lower in FY2025 due to working capital unwinding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252920,"accession_number":"0000721371-24-000012","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cardinal Health elects Robert Azelby to Board of Directors, effective March 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert W. Azelby elected as an independent director, effective March 1, 2024.","Azelby brings over 30 years of biopharma, oncology, and specialty industry experience, including CEO roles.","He will serve on the Board's Risk Oversight Committee and receive standard non-employee director compensation.","Azelby currently serves on boards of ADC Therapeutics and Autolus Therapeutics; former CEO of Eliem Therapeutics and Alder BioPharmaceuticals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252919,"accession_number":"0001193125-24-040017","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["1.01","8.01","2.03","9.01"],"status":"ready","headline":"Cardinal Health completes $1.15B senior notes offering in two tranches","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $650M of 5.125% notes due 2029 and $500M of 5.450% notes due 2034.","Offering closed February 20, 2024; underwritten by BofA, Goldman Sachs, MUFG, Wells Fargo.","Notes are senior unsecured obligations governed by base indenture and first supplemental indenture.","Legal opinions from company general counsel and Skadden, Arps filed as exhibits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252918,"accession_number":"0001628280-24-002805","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cardinal Health Q2 revenue up 12% to $57.4B; non-GAAP EPS $1.82 (+38%); FY24 guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $1.43 vs. $(0.50) prior year; non-GAAP operating earnings $562M, up 20%.","Pharmaceutical segment profit $518M (+12%); Medical segment profit $71M vs. $17M.","FY24 non-GAAP EPS guidance raised to $7.20-$7.35 from $6.75-$7.00; adj. free cash flow ~$2.5B.","Announced acquisition of Specialty Networks, a tech-enabled multi-specialty GPO and practice enhancement organization.","Revenue $57.4B, driven by brand/specialty pharmaceutical sales growth and COVID-19 vaccine distribution."],"consensus_eps_estimate":null,"consensus_eps_actual":1.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":112208000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252917,"accession_number":"0000721371-24-000005","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cardinal Health raises FY2024 non-GAAP EPS guidance to high end of $6.75–$7.00 on strong cash flow and $250M ASR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Updated FY2024 non-GAAP diluted EPS guidance to high end of $6.75–$7.00.","Executed $250M accelerated share repurchase in Q2; cash flow strength drove favorability.","Completed review of at-Home Solutions ($2.6B rev) and OptiFreight Logistics ($250M rev); will invest and develop them.","New segment structure effective Jan 1, 2024: Pharmaceutical & Specialty Solutions, GMPD, and Other.","Q2 Medical segment profit expected consistent with Q1, but on track for FY26 target of $650M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":112208000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270408,"accession_number":"0000721371-23-000094","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2023-11-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cardinal Health shareholders elect directors, ratify E&Y, approve say-on-pay; two shareholder proposals fail","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 11 director nominees elected with substantial majority (approx. 188-198M votes for, 2-12M against).","Ratified Ernst & Young as independent auditor for FY2024; 209.5M for, 10.3M against.","Say-on-pay advisory resolution approved: 182.7M for, 16.9M against.","Advisory vote on frequency: 196.2M voted for 'every year'; company will hold annual say-on-pay.","Two shareholder proposals (stock retention policy, termination pay ratification) failed; both received less than 35% support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270407,"accession_number":"0000721371-23-000083","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cardinal Health Q1 revenue +10% to $54.8B; raises FY24 non-GAAP EPS guidance to $6.75-$7.00","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP operating loss $14M due to $581M Medical goodwill impairment; GAAP diluted EPS $0.02.","Non-GAAP operating earnings $571M (+35%); non-GAAP diluted EPS $1.73 (+44%) vs. $1.20.","Pharmaceutical segment profit $507M (+18%); Medical segment profit $71M vs. ($8M) loss.","FY2024 non-GAAP EPS guidance raised to $6.75-$7.00 from $6.50-$6.75; pharma profit growth outlook raised to 7%-9%.","Interest and other expense guidance reduced to $100M-$120M; diluted shares ~249M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":54763000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287361,"accession_number":"0001193125-23-229583","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2023-09-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Cardinal Health amends $1B receivables facility; adds seller, replaces servicer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CH-23 Funding added as seller; CH-23 appointed new servicer under $1B committed facility.","Griffin Capital assigned servicer duties to CH-23; remains sub-servicer for legacy receivables.","Cardinal Health issued performance guaranty for CH-23 Funding's obligations.","Facility terms otherwise unchanged; amendment effective September 1, 2023.","Parties include MUFG, PNC, BNS, BofA, Wells Fargo, Liberty Street, Victory."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287360,"accession_number":"0000721371-23-000058","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2023-08-15T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Cardinal Health Q4 non-GAAP EPS $1.55 (+48%); raises FY24 guidance to $6.50-$6.75","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $53.5B (+13% YoY); non-GAAP EPS $1.55 (+48%) vs $1.05 prior year.","Pharmaceutical segment profit up 12% to $504M; Medical segment profit improved to $82M from -$16M.","Full-year non-GAAP EPS $5.79 (+14%), an all-time high; operating cash flow $2.8B.","FY2024 non-GAAP EPS guidance raised to $6.50-$6.75 from $6.45-$6.70; segment profit growth expected.","Director Carrie S. Cox will not stand for re-election at 2023 annual meeting; no disagreement."],"consensus_eps_estimate":null,"consensus_eps_actual":1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":205012000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307490,"accession_number":"0000721371-23-000035","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cardinal Health raises FY2023 EPS outlook, provides FY2024 guide of $6.45-$6.70, $3.5B buyback","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Narrows FY2023 non-GAAP EPS guidance to $5.65-$5.80 (mid-point 13% growth); preliminary FY2024 guidance $6.45-$6.70 (15% growth).","Long-term target: 12%-14% non-GAAP EPS CAGR over FY2024-2026; Pharmaceutical segment profit growth 4%-6%.","Board approves new $3.5B share repurchase authorization through 2027; plans at least $2B in buybacks over next three years.","Launches Navista Network for community oncology; retains and invests in Nuclear & Precision Health Solutions.","Medical Improvement Plan targets $650M+ segment profit by FY2026; $400M expected in FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307489,"accession_number":"0000721371-23-000027","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Cardinal Health amends bylaws to adopt universal proxy rule procedures","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Requires shareholder nominations include evidence of compliance with SEC universal proxy rules (Rule 14a-19).","Provides that a shareholder nomination will be disregarded if the nominating shareholder fails to comply.","Addresses the color of proxy cards reserved for use by the Company; includes technical and clarifying changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307488,"accession_number":"0001193125-23-135011","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Cardinal Health Q3 revenue +13% to $50.5B; raises FY23 non-GAAP EPS guidance to $5.60-$5.80","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $50.5B (+13% YoY); GAAP EPS $1.34 (vs -$5.05 loss); Non-GAAP EPS $1.74 (+20% YoY).","Pharmaceutical segment profit $600M (+23%); Medical segment profit $20M (-66%).","FY23 non-GAAP EPS guidance raised to $5.60-$5.80 from $5.20-$5.50; adjusted FCF raised to $2.0-$2.3B.","Cooperation agreement with Elliott extended to July 15, 2024; Business Review Committee extended similarly.","Pharmaceutical profit growth outlook raised to 10.5%-12%; Medical profit outlook lowered to ~50% decline."],"consensus_eps_estimate":null,"consensus_eps_actual":1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":151559000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326506,"accession_number":"0000721371-23-000014","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Cardinal Health enters $2.0B revolving credit facility maturing 2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$2.0 billion revolving credit facility, matures February 25, 2028, with two optional one-year extensions.","Replaces prior credit agreement; backs commercial paper program and general corporate purposes.","Financial covenant requires Consolidated Net Leverage Ratio ≤ 3.75 to 1.00.","Includes sustainability-linked pricing adjustments based on ESG Key Performance Indicators.","Interest rates based on Term SOFR plus spread tied to credit ratings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326505,"accession_number":"0000721371-23-000005","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2023-02-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cardinal Health Q2 revenue $51.5B, non-GAAP EPS $1.32; raises FY23 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $51.5B, up 13% YoY; GAAP operating loss $119M on $709M goodwill impairment in Medical segment.","Non-GAAP diluted EPS $1.32, up 4% YoY; non-GAAP operating earnings $467M, flat YoY.","Pharmaceutical segment profit $464M (+9%); Medical segment profit $17M (-66%).","FY23 non-GAAP EPS guidance raised to $5.20-$5.50 from $5.05-$5.40; pharma profit growth outlook raised to 4-6.5%.","Interest and other lowered to $115M-$130M from $140M-$160M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":101072000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344228,"accession_number":"0000721371-22-000181","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2022-12-19T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cardinal Health appoints Aaron Alt as CFO effective Feb 10, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Aaron Alt, 51, named CFO effective Feb 10, 2023; succeeds interim CFO Trish English.","Alt previously EVP & CFO of Sysco Corporation; also CFO of Sally Beauty and senior roles at Target.","Compensation: base salary $825,000, target bonus 110% of salary, long-term incentives $3.5M, plus $1M sign-on and equity grants.","Alt will lead financial strategy, capital deployment, treasury, tax, IR, accounting, reporting, and corporate development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344227,"accession_number":"0000721371-22-000144","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cardinal Health shareholders elect 13 directors, ratify auditor, approve exec comp at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 13 director nominees elected; most with ~202M votes for, fewer than 1M against.","Ernst & Young ratified as auditor for FY ending June 30, 2023: 220.5M for, 8.3M against.","Non-binding advisory vote on executive compensation approved: 185.0M for, 18.3M against.","Broker non-votes on director elections and say-on-pay: 25.1M each; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344226,"accession_number":"0000721371-22-000131","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2022-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cardinal Health Q1 FY23 revenue up 13% to $49.6B; GAAP EPS $0.40, non-GAAP EPS $1.20; Medical segment posts loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP operating earnings $137M, including $154M goodwill impairment; GAAP diluted EPS $0.40, down 57% YoY.","Non-GAAP operating earnings $423M (-20% YoY); non-GAAP diluted EPS $1.20 (-7% YoY).","Pharmaceutical segment profit up 6% to $431M; Medical segment loss of $8M vs $123M profit prior year.","Revised FY23 Medical segment profit outlook to flat to 20% decline; reaffirms non-GAAP EPS guidance $5.05-$5.40.","Updated FY23 interest/other expense to $140M-$160M, non-GAAP tax rate 23%-24%, diluted shares ~262-264M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":49603000000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344225,"accession_number":"0000721371-22-000127","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2022-10-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Cardinal Health extends $1.0B receivables facility to Sept 2025; adds BofA as participant","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended $1.0B committed receivables sales facility from Sept 30, 2022 to Sept 30, 2025.","Added Bank of America as a participant with $250M commitment; removed Credit Agricole and U.S. Bank.","Replaced LIBOR-based interest rate benchmark with daily term SOFR.","MUFG Bank remains agent; Wells Fargo, PNC, BofA, and others continue as participants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":360726,"accession_number":"0000721371-22-000105","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2022-09-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Cardinal Health cuts Medical segment Q1 FY23 guidance to $55M-$25M loss on glove inventory charges","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Medical segment loss expected $55M-$25M for Q1 FY23, down from prior range of $20M loss to $20M profit.","Inventory charges of ~$25M from gloves portfolio simplification, including sale of disposable gloves for non-healthcare industries.","Reaffirmed FY2023 non-GAAP diluted EPS guidance of $5.05-$5.40.","Presentation at Morgan Stanley conference scheduled for Sept 13, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":360725,"accession_number":"0000721371-22-000101","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2022-09-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cardinal Health announces Pharmaceutical Segment CEO change; Crawford out, Weitzman in","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Victor Crawford to step down as Pharmaceutical Segment CEO effective Sept 19, 2022; will stay until Nov 13 for transition.","Debbie Weitzman, former President of Pharmaceutical Distribution, named new CEO of Pharmaceutical Segment.","Role of President of Pharmaceutical Distribution eliminated; segment restructured with additional role eliminations.","Pharmaceutical and Specialty Distribution businesses will both report directly to Weitzman."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":360724,"accession_number":"0000721371-22-000096","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2022-09-06T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Cardinal Health appoints 4 new directors, forms Business Review Committee in Elliott cooperation deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four new independent directors appointed: Steven Barg (Elliott), Michelle Brennan, Sujatha Chandrasekaran, Christine Mundkur, effective Sept 6, 2022.","Two directors (Dean Scarborough, John Weiland) will not stand for re-election at 2022 Annual Meeting, reducing board to 13 members.","New Business Review Committee formed, chaired by CEO Jason Hollar, plus Steven Barg and Akhil Johri, to review strategy, portfolio, capital allocation, and operations.","Elliott entered cooperation agreement with standstill, voting, and confidentiality provisions; investor day expected in H1 2023.","Board composition will become 54% women and 23% racially/ethnically diverse following the Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":360723,"accession_number":"0000721371-22-000059","cik":721371,"company_name":"CARDINAL HEALTH INC","ticker":"CAH","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cardinal Health names CFO Jason Hollar as CEO effective Sept 1; Patricia English interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason Hollar, 49, elected CEO effective Sept 1, 2022, succeeding Michael Kaufmann who departs.","Hollar compensation: base salary $1.35M, target bonus 150%, LTI $11M, plus $3M alignment grant.","Patricia English (CAO) appointed Interim CFO effective Sept 1; base $300K, $250K retention through Aug 2023, $500K PSUs.","Mary Scherer, previously SVP Internal Audit, promoted to SVP & Chief Accounting Officer effective Sept 1.","Kaufmann resigns from Board Sept 1; eligible for severance under Senior Executive Severance Plan subject to release and covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":46803697187.17333,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-11T23:59:59+00:00|360723"}